Endonovo Therapeutics, Inc. (ENDV)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jan 22, 2026, 4:00 PM EST
Endonovo Therapeutics Revenue
Endonovo Therapeutics had revenue of $1.52K in the quarter ending September 30, 2023, a decrease of -86.13%. This brings the company's revenue in the last twelve months to $255.72K, up 1,699.85% year-over-year. In the year 2022, Endonovo Therapeutics had annual revenue of $135.36K with 85.15% growth.
Revenue (ttm)
255.72K
Revenue Growth
+1,699.85%
P/S Ratio
0.71
Revenue / Employee
255.72K
Employees
1
Market Cap
180.76K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 135.36K | 62.25K | 85.15% |
| Dec 31, 2021 | 73.11K | -92.69K | -55.91% |
| Dec 31, 2020 | 165.80K | -144.37K | -46.55% |
| Dec 31, 2019 | 310.16K | 226.90K | 272.51% |
| Dec 31, 2018 | 83.26K | - | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hemagen Diagnostics | 4.04M |
| Scorpius Holdings | 2.41M |
| Eastgate Biotech | 137.64K |
| GB Sciences | 97.24K |
| CNBX Pharmaceuticals | 40.64K |
| THC Farmaceuticals | 18.52K |
| Oncology Pharma | 10.21K |
Endonovo Therapeutics News
- 1 year ago - Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc - GlobeNewsWire
- 2 years ago - Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions - GlobeNewsWire
- 2 years ago - Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million - GlobeNewsWire
- 2 years ago - Endonovo's SofPulse® Secures Taiwan FDA Approval - GlobeNewsWire
- 2 years ago - Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution - GlobeNewsWire
- 2 years ago - Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update - GlobeNewsWire
- 2 years ago - Endonovo Pending Agreement to Develop Telehealth Division - GlobeNewsWire
- 2 years ago - Endonovo Launches SofPulse® into the Veterans Administration - GlobeNewsWire